Skip to main content
Premium Trial:

Request an Annual Quote

CRISPR-Chip Maker Cardea Bio Raises $7.5M in First Close of Series A2 Financing Round

NEW YORK – Cardea Bio said on Thursday that it has raised $7.5 million in the first close of a Series A2 financing round.

The round was led by a partnership of venture capital firms, including Tsingyuan Ventures, Lifespan Investments, and longtime Cardea investor Serra Ventures, as well as Agilent Technologies, Table Mountain Capital, Photon Fund, and Taihill Venture, the company said.

Cardea plans to use the capital to accelerate the growth and development of its infrastructure and CRISPR-based chips. The CRISPR-Chip, the company's flagship product, is a CRISPR-Cas9-based biosensor diagnostic device that uses a graphene transistor. Cardea has demonstrated the chip's utility in detecting Duchenne muscular dystrophy, and was looking to develop additional disease diagnostics, agricultural tools, and research tools using the same idea.

In September 2019, Cardea merged with Nanosens Innovations, the company it had teamed up with to develop the CRISPR-Chip. Concurrent with the merger, Cardea set up what it called an innovation partnership program, under which it accepted suggestions from potential partners on possible uses for the CRISPR-Chip. Since then, the company said it has received interest in potential product development partnerships from hundreds of companies, and expects the first "Powered by Cardea" chip products to launch in 2020 and 2021.

"We envision a future where 'Powered by Cardea' products, all running on the same type of chipsets, will significantly impact and improve large markets from human health, agriculture, food and water safety, diagnostics, and environmental monitoring to quality control, security, and drug development," Cardea Chief Business Officer Rob Lozuk said in a statement.

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.